Literature DB >> 12040862

Current oral agents for type 2 diabetes. Many options, but which to choose when?

Andrew J Ahmann1, Matthew C Riddle.   

Abstract

Increasingly, type 2 diabetes takes a toll on public health and healthcare costs in the United States. Although the remedy for this growing problem is very complex, two critical components of its control are prevention and effective therapy. Progress in diabetes prevention is likely to take decades. But fortunately, growth in our understanding of what occurs in this chronic disease has led to advances in the pharmacologic options aimed at decreasing hyperglycemia, the main clinically measurable metabolic consequence of diabetes. In this article, Drs Ahmann and Riddle provide an overview of the oral agents now available for the treatment of diabetes and discuss the clinical factors that help determine when to use which medication and what outcome to expect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12040862     DOI: 10.3810/pgm.2002.05.1194

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  3 in total

1.  Medicaid managed care: disparities in the use of thiazolidinediones compared with metformin.

Authors:  Fadia T Shaya; James Y Shin; Daniel Mullins; Hugh O Fatodu; Anna Gu; Elijah Saunders
Journal:  J Natl Med Assoc       Date:  2005-04       Impact factor: 1.798

2.  Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy.

Authors:  Giuseppe Derosa; Sibilla Anna Teresa Salvadeo
Journal:  Core Evid       Date:  2008-02-29

Review 3.  Complexity of type 2 diabetes mellitus data sets emerging from nutrigenomic research: a case for dimensionality reduction?

Authors:  Jim Kaput; Kevin Dawson
Journal:  Mutat Res       Date:  2007-05-05       Impact factor: 2.433

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.